



José Baselga, MD, PhD
(1959, Barcelona, Spain)

Dr. Baselga is the newly-appointed Physician-in-Chief at Memorial Sloan-Kettering Cancer Center. Most recently he served as associate director of the Massachusetts General Cancer Center and chief of the Division of Hematology/Oncology at Massachusetts General Hospital, where he was also professor of Medicine at Harvard Medical School.

Dr. Baselga's research interests are in clinical breast cancer and in translational and early clinical research. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and is leading the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and in the clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents and therapeutic approaches to target the PI3K pathway. He is also leading a number of neo-adjuvant trials in breast cancer and has been at the forefront of developing biomarker-based early and translational clinical trials. Most recently he has led the early clinical development and has been principal investigator of the two large phase III studies with pertuzumab in HER2 and everolimus in ER+ breast cancer. These two agents have been recently approved for the therapy of patients with breast cancer and have opened new options for patients with advanced disease.

Dr. Baselga is a past member of the American Association of Cancer Research Board of Directors, a past President of European Society of Medical Oncology and a past member of the Board of Directors of American Society of Clinical Oncology and a member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research. Dr. Baselga has received a number of awards including a Young Investigator Award (1992) and a Career Development Award from ASCO (1994), a Bristol-Myers Squibb Unrestricted Cancer Grant Award (2002-2006), Elected Member of the American Society of Clinical Investigation (2004); AACR-Rosenthal Family Foundation Award (2008); and King James I Award (2008) He is a member of the Editorial Boards of Cancer Cell, Clinical Cancer Research and Annals of Oncology and he is the funding editor-in-chief on the new flagship journal Cancer Discovery. Dr. Baselga has published over 300 peer-reviewed articles.

In addition to his research and administrative functions, Dr. Baselga is a gifted and caring physician that is also deeply involved in teaching and mentoring young physician scientists.

Dr. Baselga is originally from Barcelona, Spain, and received his MD and PhD from the Universidad Autonoma of Barcelona. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York and subsequently stayed on as a faculty member of the Breast Medicine Service at Memorial Sloan-Kettering. From 1996 to 2010 he was the chairman of the Medical Oncology Service and founding director of Vall d'Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona, Spain.